- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Genentech and UC Settle Patent Battle
16 November 1999 6:00 pm
One of the longest patent fights in biotech history may at last be over. Today, the Los Angeles Times reported that Genentech Inc. of South San Francisco had agreed to pay the University of California (UC) $200 million for having infringed on UC's patent on a genetically engineered human growth hormone.
A trial on the decade-old infringement case ended with a hung jury in June (Science, 11 June, p. 1752). Now, a scheduled January retrial appears to have been averted.
According to the Times, nearly half of the settlement will be split among the five scientists named as co-discoverers on the patent, and the remainder will go to UC San Francisco, with $50 million earmarked to fund a new research building. Today, UC and Genentech were staying silent on the deal until the UC Regents had a chance to review it at a meeting earlier this week.